Detected ·
Remix Therapeutics
$100M—
Remix Therapeutics announced a merger agreement with Passage Bio and closed an oversubscribed $100M private placement financing to advance its RNA-targeted small-molecule therapies, led by REM-422 in Phase 2 trials.
- Website
- www.remixtx.com
- Amount
- $100 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-06-25 16:11:41 UTC
- Signal ID
- 4b997f9b-bd04-4acd-823a-ab861613c596
As the API returns it
{
"id": "4b997f9b-bd04-4acd-823a-ab861613c596",
"created_at": "2026-06-25T16:11:41.293224Z",
"company_name": "Remix Therapeutics",
"company_website_url": "www.remixtx.com",
"company_linkedin_url": "https://www.linkedin.com/company/remix-therapeutics",
"event_type": "funding",
"funding_amount": 100000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Remix Therapeutics announced a merger agreement with Passage Bio and closed an oversubscribed $100M private placement financing to advance its RNA-targeted small-molecule therapies, led by REM-422 in Phase 2 trials.*"
}